A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC).
A. Johnsson
Research Funding - Roche
J. Frodin
No relevant relationships to disclose
A. Berglund
Honoraria - Seminar presentations
H. Hagman
No relevant relationships to disclose
J. Sundberg
No relevant relationships to disclose
D. Bergstrom
Employment or Leadership Position - Roche
R. d. Christensen
Consultant or Advisory Role - Roche
Honoraria - Roche
N. Keldsen
No relevant relationships to disclose
K. G. Spindler
No relevant relationships to disclose
A. K. M. Jakobsen
Honoraria - Roche
Research Funding - Roche